![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/13/2929090/0/en/Abeona-Therapeutics-Announces-Favorable-Medicare-Reimbursement-Decisions-for-Pz-cel.html
https://www.globenewswire.com/news-release/2024/08/12/2928295/0/en/Abeona-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Concludes-Type-A-Meeting-with-FDA-to-Align-on-Upcoming-Pz-cel-BLA-Resubmission.html
https://www.globenewswire.com/news-release/2024/08/01/2922672/0/en/Abeona-Therapeutics-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/07/11/2911728/0/en/Abeona-Therapeutics-and-Beacon-Therapeutics-Announce-Non-Exclusive-Agreement-for-Beacon-to-Evaluate-Therapeutic-Potential-of-Abeona-s-Patented-AAV204-Capsid-for-Select-Ophthalmolog.html
https://www.globenewswire.com/news-release/2024/07/08/2909532/0/en/Abeona-Therapeutics-to-Present-at-the-Stifel-Virtual-Cell-Therapy-Forum.html
https://www.globenewswire.com/news-release/2024/06/03/2892138/0/en/Abeona-Therapeutics-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/28/2888920/0/en/Abeona-Therapeutics-to-Present-at-the-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/15/2882305/0/en/Abeona-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Recent-Corporate-Progress.html
https://www.globenewswire.com/news-release/2024/05/07/2876617/0/en/Abeona-Therapeutics-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/03/2875048/0/en/Abeona-Therapeutics-Announces-Pricing-of-75-Million-Underwritten-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html